TScan Therapeutics, Inc. business relationships
Companies named in TScan Therapeutics, Inc.’s 10-K filed 2026-03-04, and public companies whose annual reports name TScan Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 46 / 100 Top 1% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in TScan Therapeutics, Inc.’s annual report 4
“The Company concluded that Amgen meets the definition of a customer, as the Company is delivering research and development activities and a license of intellectual property.” SEC filing
“To date, we have a research collaboration and license agreement with Amgen to identify the antigens recognized by T cells in patients with Crohn's disease.” SEC filing
“Collaboration and License Agreement by and between the Registrant and Novartis Institutes for Biomedical Research, dated as of March 27, 2020 (incorporated by reference to Exhibit 10.8 to the Registrant's Registration Statement on S-1 filed with the Securities and Exchange Commission on April 23, 20...” SEC filing
“In addition, the Company is continuing to discover targets for Crohn's disease in partnership with Amgen.” SEC filing
Companies whose annual reports name TScan Therapeutics, Inc. 1
“Specifically in regard to PRAME, we are aware that Immatics, TScan Therapeutics, Inc., and Replay Therapeutics, Inc. (in collaboration with MD Anderson) are conducting Phase 1 clinical trials of PRAME-directed cellular therapies and Immatics has also initiated a Phase 1/2 clinical trial of a PRAME T...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.